TuHURA Biosciences, Inc. (NASDAQ:HURA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

TuHURA Biosciences, Inc. (NASDAQ:HURA) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $9.00.

Several research analysts have recently issued reports on HURA shares. Wall Street Zen cut shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, May 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Friday, July 17th. Finally, Citizens Jmp restated a “market outperform” rating and issued a $9.00 price objective on shares of TuHURA Biosciences in a research note on Tuesday, August 18th.

TuHURA Biosciences Stock Up 0.5%

Shares of NASDAQ HURA opened at $2.10 on Friday. The business has a 50-day moving average of $2.16 and a two-hundred day moving average of $2.19. The company has a market capitalization of $133.83 million, a price-to-earnings ratio of -3.89 and a beta of -0.02. TuHURA Biosciences has a 1 year low of $0.41 and a 1 year high of $3.43. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.18 and a quick ratio of 0.18.

TuHURA Biosciences (NASDAQ:HURA) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. On average, analysts forecast that TuHURA Biosciences will post -0.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TuHURA Biosciences

A number of hedge funds have recently modified their holdings of HURA. Two Sigma Securities LLC acquired a new position in TuHURA Biosciences in the second quarter valued at $33,000. Merck & Co. Inc. purchased a new position in shares of TuHURA Biosciences during the second quarter worth about $45,501. Sanctuary Advisors LLC purchased a new stake in TuHURA Biosciences during the 2nd quarter valued at approximately $49,000. Deutsche Bank AG purchased a new position in shares of TuHURA Biosciences in the 2nd quarter valued at approximately $52,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of TuHURA Biosciences during the second quarter worth $69,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

About TuHURA Biosciences

TuHURA Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is aimed at addressing primary and acquired resistance to existing cancer immunotherapies, including immune checkpoint inhibitors.

TuHURA’s lead investigational product, IFx-2.0, is an intratumoral cancer immunotherapy designed to stimulate a patient’s immune system to recognize and attack tumor cells. The company is evaluating the candidate in clinical studies involving advanced solid tumors, including melanoma, with the goal of improving responses in patients whose cancers have not responded adequately to available treatments.

TuHURA is headquartered in Tampa, Florida, and conducts its drug-development activities through clinical research and collaborations primarily in the United States.